Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ICML 2019 | Opportunistic infections during ibrutinib treatment for B-cell malignancies

Kerry Rogers • 19 Jun 2019
ICML 2019
Chronic Lymphocytic Leukemia Leukemia Ibrutinib

Kerry Rogers, MD, from the Ohio State University, Columbus, OH, discusses the risk of opportunistic infections during ibrutinib treatment for B-cell malignancies, including chronic lymphocytic leukemia (CLL). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Kerry Rogers

The potential role of therapies targeting surface antigens in the CLL treatment landscape
1:48
The potential role of therapies targeting surface antigens in the CLL treatment landscape
Kerry Rogers • 13 Sep 2025
Improving the targeting of surface antigens in CLL: moving beyond monoclonal antibodies
4:20
Improving the targeting of surface antigens in CLL: moving beyond monoclonal antibodies
Kerry Rogers • 13 Sep 2025
The management of double-refractory CLL: current options and approaches being explored
3:04
The management of double-refractory CLL: current options and approaches being explored
Kerry Rogers • 13 Sep 2025
Key updates in hairy cell leukemia from ASH 2024
5:12
Key updates in hairy cell leukemia from ASH 2024
Kerry Rogers • 9 Dec 2024

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Kerry Rogers • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Kerry Rogers • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Kerry Rogers • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Kerry Rogers • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals